Foundation Medicine will develop a companion diagnostic test for use with a Clovis Oncology drug now in mid-stage clinical trials to treat patients with ovarian cancer.
After a rough go with the FDA sent its shares spiraling downward, Amarin has at last found a partner to help commercialize its fish-oil-derived pill for high triglycerides.
Rival drugmakers Merck KGaA and Pfizer are putting their cash and expertise into a new effort to better understand lupus, tapping the Broad Institute for a Big Data approach to help map out the disease and light the way for future drug candidates.
Close to a year after Forma Therapeutics' executive team hammered out a partnership with Celgene packed with $200 million in early-stage payouts, the big biotech outfit has come back with a $600 million discovery deal that might eventually lead the pair to the M&A altar.
AstraZeneca isn't due to move into its new Cambridge, U.K., headquarters for another two years, but the British giant is already laying the groundwork for open collaboration in the biomedical hub, signing a deep-seated deal with the government-run Medical Research Council to work on drug discovery.
CRO BioClinica said it inked two long-term deals with major drugmakers totaling $30 million, touting its eClinical technology as driving sponsor interest.
A month removed from a $915 million buyout deal, CRO Medpace has signed on to help biotech NephroGenex get through Phase III with its promising kidney disease candidate.
Raleigh, NC's BioDelivery Sciences is expecting to win FDA approval for its opioid-dependence patch this summer, and the biotech has enlisted global contractor Quintiles to handle the launch.
AstraZeneca has struck up a partnership with the Shenzhen University Health Science Center in Shanghai to collaborate on preclinical work for chronic kidney disease treatments, a growing problem among China's aging population.
Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson.